Hemab Therapeutics Holdings, Inc. (COAG)

Market Cap	1.20B
Revenue (ttm)	n/a
Net Income	-63.91M
EPS	-67.56
Shares Out	44.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,181
Open	27.62
Previous Close	28.07
Day's Range	25.42 - 27.94
52-Week Range	23.00 - 36.61
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 2, 2026

About COAG

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 1, 2026
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: COAG
• Website: https://www.hemab.com